Money already collected for work not yet done: the company is sitting on customer-funded obligations that dwarf what it
The model's full reasoning — Q4 2022 call → NOWe need answer YES or NO. Need analyze transcript. Question asks: Does management describe that customers/counterparties have already put money or irreversible commitment into company for things not yet delivered, and does management treat that accumulated unearned obligation as large relative to current business, with work of discharging it now central task? We need look for evidence. Transcript: Adaptive Biotechnologies. Revenue includes MRD pharma partnerships, milestones, Genentech upfront amortization. Genentech collaboration: upfront payment received, amortized over time. They mention "Genentech amortization" as revenue. In 2023, "significantly lower amortization from the Genentech upfront versus prior years." Also "we recognized 7 million of the 10 million upfront on the acceptance of that milestone." Wait, Genentech upfront was received earlier, being amortized. That is deferred revenue? They have obligation to perform R&D. But is it described as large relative to current business? They mention Genentech amortization headwind. But question asks customers/counterparties have already put money or irreversible commitment ahead of delivery, and company still owes performance, and obligation large relative to current business, central task. Need see if management describes that. They discuss pharma services, drug discovery partnerships. Genentech upfront is a payment received for collaboration, amortized over time. But is it "unearned obligation" large? They don't explicitly discuss deferred revenue balance. They mention "Genentech amortization" as revenue recognition. Also MRD milestones from drug approvals: "recognized a $2 million milestones from approval of another multiple myeloma therapy, which use our clonoSEQ assay as a secondary endpoint." That's milestone payments for past achievement, not unearned. Also "MRD pharma partnerships" revenue from pharma using clonoSEQ in trials. They may have contracts with milestones. But not described as prepayments. Question specifically: "customers or counterparties have already put money or irreversible commitment into the company for things the company has not yet delivered" and "management treat that accumulated, unearned obligation as large relative to current level of business, with work of discharging it now central task." This sounds like deferred revenue / backlog.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
KOPN · Q4 2023 → YESThe question is about whether management describes customers having already put money or irreversible commitment into the company for things not yet delivered, treating that as large relative to curre...
SYM · Q3 2022 → YESThe question is about whether management describes customers having already put money or irreversible commitment into the company for things not yet delivered, treating that as large relative to curre...
VNRX · Q1 2022 → YESThe question is about whether management describes customers or counterparties having already put money or irreversible commitment into the company for things not yet delivered, treating that as large...